With these latest clearances, Restore Robotics continues to deliver on its mission to provide hospitals and surgery centers with cost-effective, high-quality, and sustainable alternatives to purchasing new robotic instruments from original equipment manufacturers.

“These additional FDA clearances mark another major step forward in our effort to transform the economics of robotic surgery,” said Clif Parker, CEO of Restore Robotics. “By expanding our remanufacturing capabilities across more high-utilization instruments, we are enabling healthcare providers to significantly reduce costs while maintaining the performance and reliability surgeons expect.”